Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
200 participants should be included in the study. There will be three groups: 100 participants with a severe course of the disease 3 months ago, 50 asymptomatic carriers of coronavirus infection 3 months ago and 50 people who were in close contact with patients with confirmed coronavirus infection 3 months ago, but not sick and without antibodies to SARS-CoV-2.
The study consists of two visits. At the first visit, after signing the consent to participate in the study, a screening examination will be performed to assess the criteria for inclusion and exclusion in the study.
At the second visit, patients who meet the inclusion criteria and do not have exclusion criteria will undergo clinical and instrumental examination, and biological samples will be collected for laboratory testing.
The aim of the study is to determine the most significant clinical and laboratory markers of the severity of the outcomes in the period of convalescence of the new coronavirus infection COVID-19. Clinical and laboratory indicators, the number and severity of signs of postcovid syndrome as well as pathological changes in lung tissue according to CT data in the group with covid pneumonia and indicators of immune status, hemostasis, endothelial dysfunction, inflammation, metabolism will be assessed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with severe COVID-19 pneumonia |
| ||
| Patients who had an asymptomatic COVID-19 3 months ago |
| ||
| People who had close contact with patients with confirmed COVID-19 3 months ago but did not get sick |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Laboratory and instrumental examination | Diagnostic Test | All patients will undergo a comprehensive examination to identify the consequences of COVID-19 |
|
| Measure | Description | Time Frame |
|---|---|---|
| The presense of postcovid syndrome | Clinical and laboratory indicators The number and severity of signs of postcovid syndrome | through study completion, an average of 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Pathological changes in lung tissue according to CT data | CT scan | through study completion, an average of 3 months |
Not provided
Inclusion Criteria:
For all groups:
Group COVID-19 (asymptomatic):
Group Healthy:
Group COVID symptomatic:
Confirmed diagnosis of previous COVID-19 (positive SARS-CoV-2 RNA PCR test or presence of IgM antibodies to SARS-CoV-2) in history.
A severe course of COVID-19, characterized by one or more of the following symptoms:
Exclusion Criteria:
Not provided
Not provided
Not provided
Men and women aged 18 and over with asymptomatic or severe course of the novel coronavirus infection COVID-19, or who have been in close contact with patients with confirmed coronavirus infection, but who are not sick and do not have antibodies to SARS-CoV-2
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daria Kashtanova, MD, PhD | Contact | dr.kashtanova@gmail.com | ||
| Olga Tkacheva, MD, PhD | Contact | rgnkc@rgnkc.ru |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Russian Clinical Research Center for Gerontology | Recruiting | Moscow | 129226 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |